Blinatumomab added to chemotherapy improves disease-free survival in newly diagnosed NCI standard risk paediatric B-ALL
Blinatumomab added to chemotherapy improves disease-free survival in newly diagnosed NCI standard risk paediatric B-ALL
Demographics, characteristics, survival and outcomes in older, untreated, AML with NPM1 mutations or KMT2A rearrangements
Guiding metastasis-directed therapy with different PET/CT radiotracers affects distant disease control in HSPC patients
Bladder cancer updates from the second half of 2024
30 minute infusion of isatuximab shows potential in newly diagnosed multiple myeloma
EMUC 2024: Optimising strategies in mHSPC and mCRPC
SIOG 2024: Updates in haematology
CDK4/6 inhibitors and endocrine therapy in elderly female patients with advanced hormone receptor positive HER-2 negative BC
Understanding the remaining unmet needs in a post ASCT NDMM setting
ESMO and WCLC: Latest developments in EGFR mutated NSCLC
Choosing the right Tyrosine Kinase Inhibitors (TKI) for CML Patients
Advancements in head and neck cancer treatment in India